Jasbg, AMRN could announce a buyback, and not use it unless the stock
falls to a "stupid" level...In the meantime, the prospect of a buyback
should help to support the share price. HDGabor has given us his final
take on AMRN. I think he is wrong about the valuation in a BO as I
believe Europe could still be a monster market for a much needed drug.
My take is that only with a BP BO will Vascepa reach optimized sales.
GIA is still a "fools errand."
Because JT is this ship's captain, he needs to quickly right the ship
and get back on course. If he fails to do that soon he should be
removed and replaced with a competent captain. JT should have sold the
company after R-I results came out. That was obvious. Now, it is
obvious that AMRN should be sold so a BP can launch Vascepa in Europe
properly and extend protections there. BP can do that...JT cannot.
News 
Market Data 
Discover 
AI
